Page 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 10 - Q × QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30 , 2021 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Delaware to Commission File Number : 001-36304 Phio Pharmaceuticals Corp. ( Exact name of registrant as specified in its charter ) ( State of incorporation ) Title of each class 45-3215903 ( I.R.S. Employer Identification No. ) 257 Simarano Drive , Suite 101 , Marlborough , MA 01752 ( Address of principal executive office ) ( Zip code ) Registrant's telephone number : ( 508 ) 767-3861 Securities registered pursuant to Section 12 ( b ) of the Act : Common Stock , par value , $ 0.0001 per share Trading Symbol ( s ) PHIO Name of each exchange on which registered The Nasdaq Capital Market Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the Registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes + No □ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter time that the registrant was required to submit such files ) . Yes No □ Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , ” “ accelerated filer , ” “ smaller reporting company , " and " emerging growth company ” in Rule 12b - 2 of the Exchange Act . Large accelerated filer Non - accelerated Filer ☐ Accelerated filer ☑ Smaller reporting company Emerging growth company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by checkmark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes No As of August 6 , 2021 , Phio Pharmaceuticals Corp. had 13,534,389 shares of common stock , $ 0.0001 par value , outstanding . ☐ ☐ ☐